Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Amanda F, Hanke, Neale T, Sands, Barbara J, Carbajal, Liliana, Anderl, Janet L, Garland, Linda L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304157/
https://www.ncbi.nlm.nih.gov/pubmed/25612802
http://dx.doi.org/10.1186/s13046-014-0111-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304157/
https://www.ncbi.nlm.nih.gov/pubmed/25612802
http://dx.doi.org/10.1186/s13046-014-0111-8

Ejemplares similares